Tender seeks advanced DNA sequencing, PCR and oncology profiling platforms, signalling ongoing investment in genetic and molecular diagnostics.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
ESTAR - Ente di Supporto Tecnico Amministrativo Regionale has opened a contract for a new generation of analytical platforms to support high-end genetic investigations, from DNA sequencing to oncology-focused molecular profiling.
On 19th May 2026, ESTAR published a contract notice for the supply of advanced analytical systems dedicated to genetic work. The contract focuses on equipping laboratories for genetic investigations and oncology-related molecular profiling.
The notice specifies four main categories of technology:
By bundling sequencing, real-time PCR, array-based analysis and oncology-focused molecular profiling into a single procurement, ESTAR is seeking a broad platform mix for genetic investigations. The combination points to a need to support different analytical approaches within the same infrastructure, from targeted assays to more comprehensive profiling, including in cancer-related applications.
This contract sits within a wider run of tenders for genetic and molecular systems. In December 2025, Latvijas Universitāte published a notice for Laboratory Equipment for Genomics, covering genetic analysis systems, real-time PCR systems and other devices needed to establish a genomics platform.
Also in December 2025, IZSAM - Istituto Zooprofilattico Sperimentale dell Abruzzo e del Molise G. Caporale launched a procurement titled Supply of Sequencing Instrument for its Molecular Biology and Omic Technologies Department. Together, these notices show research and academic institutions expanding their capacity in sequencing and real-time PCR alongside clinical laboratories.
By March 2026, hospital laboratories were also seeking to upgrade genomic analysis. ASST DI CREMONA issued a notice for Supply of Sequencing Systems, seeking sequencing platforms and diagnostic solutions for genomic analysis and variant identification. ESTAR’s requirement for automated DNA sequencing systems aligns with this push to strengthen sequencing capacity across multiple sites.
The ESTAR contract includes real-time PCR platforms as a core component. Comparable notices from early 2026 underline how central this technology has become for routine molecular diagnostics.
In January 2026, AULSS N 1 DOLOMITI went to market with Supply of Analytical Systems for molecular biology investigations. That notice focuses on Real Time PCR technology for sexually transmitted diseases, gastrointestinal infections and analyses for transplanted and immunocompromised patients, underlining the breadth of applications expected from modern PCR platforms.
In February 2026, Azienda Sanitaria Provinciale di Messina published a procurement titled Service Supply for PCR System, seeking an analytical system for biomolecular analyses in real-time PCR for HPV-DNA determination, together with the necessary consumables for its Cytopathology and Molecular Biology service. The ESTAR tender’s inclusion of real-time PCR systems reflects the same expectation that genetic and molecular laboratories must handle both broad genomic work and focused diagnostic assays.
While ESTAR’s notice emphasises the supply of high-spec instruments, several recent procurements show how buyers are increasingly bundling equipment, reagents and support into integrated, often multi-lot, contracts.
In April 2026, Azienda ospedaliera Novara launched Analytical Systems for Genetics, a full service supply of integrated and automated analytical systems for nucleic acid extraction and genetic variant research, including a complete automatic extractor with instrumentation, reagents and consumables.
In March 2026, A.O. SAN GIUSEPPE MOSCATI published a notice for Supply of NGS Diagnostic Kits, covering diagnostic kits and consumables for next generation genetic sequencing supported by high productivity automatic preparers for a genetics laboratory.
Another example comes from January 2026, when the contracting authority identified as ORG-0001 issued a procurement titled Supply of Reagents and Instruments. That contract combines reagents with rental instruments for molecular diagnostics and sequencing of microorganisms, divided into five lots tailored to different microbiology and virology needs.
In May 2026, Azienda Sanitaria Provinciale di Siracusa published Supply of Analytical Systems for Hospitals, an open procedure for full-risk service analytical systems for Clinical Pathology Units across several hospital facilities, with multiple lots including serum area systems, automated diagnostic systems and molecular diagnosis equipment.
Against this backdrop, ESTAR’s focus on securing a suite of advanced platforms for genetic investigations and oncology profiling adds another significant contract to a procurement pipeline where many buyers now expect suppliers to provide instruments, reagents, consumables and long-term support as a package.
The ESTAR notice does not limit itself to sequencing and PCR; it also calls for CGH-array slide scanning instruments. That requirement mirrors activity in molecular cytogenetics seen elsewhere in recent months.
In December 2025, IRCCS Policlinico San Martino published a tender for Supply of FISH Consumables, divided into four lots of probes for molecular cytogenetic analysis using fluorescence in situ hybridization. Taken together, these notices indicate that cytogenetic techniques such as CGH arrays and FISH remain a key part of the toolkit for genetic investigations, alongside newer sequencing-based approaches.
The ESTAR contract brings together automated DNA sequencing, real-time PCR, CGH-array scanning and oncology-focused molecular profiling in a single procurement. Set against a series of recent notices for sequencing instruments, NGS kits, PCR platforms and full-service diagnostic systems, it underlines the extent to which laboratories are renewing and expanding their genetic and molecular capabilities.
Once awarded, the contract will help define the mix of technologies available for genetic investigations and oncology work in the laboratories it serves. Suppliers and laboratories alike will watch how this and neighbouring procurements are implemented, and how different platforms are combined in practice to deliver the next phase of genetic and molecular analysis.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.